A MULTI-ARM PHASE 1 DOSE ESCALATION STUDY OF THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF THE DUAL PI3K/MTOR INHIBITORS PF-04691502 AND PF-05212384 IN COMBINATION WITH EXPERIMENTAL OR APPROVED ANTICANCER AGENTS IN PATIENTS WITH ADVANCED CANCER.
This clinical trial is being done to study three investigational drugs called PD-0325901, PF-05212384, and PF-04691502. These study drugs are being looked at to see if they could be a treatment for advanced cancer. You will be given only one of the three
IRB Protocol #
ALISON SUTTON at (720)848-0601 or ALISON.SUTTON@UCDENVER.EDU
University of Colorado Hospital University of Colorado Hospital
Eligibility and Other Participant Information
What To Expect : A screening period will take place to determine eligibility. The number of treatment cycles you receive will depend on how you are doing. You may continue to receive the study drug for up to a year or until your disease progresses or if you develop side-effects. However, you may continue with the study drug if your study doctor determines that your cancer is not growing. Follow up visits will occur once the study concludes. // Those who are 18 years or older with advanced cancer may be eligible for to participate in this study.Those who are 18 years or older with advanced cancer may be eligible for to participate in this study.